Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Keratoacanthomas (KAs) are a well-known cutaneous side effect of BRAF inhibitors and multiple lesions continue to develop throughout the course of therapy. We present a case of an 81-year old women diagnosed with metastatic melanoma who underwent six weeks of vemurafenib therapy. She developed multiple vemurafenib-induced KAs and applied a 5% imiquimod cream three times a week. KAs successfully treated with topical application of imiquimod cream and clearance of these lesions was further confirmed by dermoscopic examination. Topical imiquimod can be an effective treatment option for the noninvasive management of multiple KAs induced by vemurafenib treatment.
a Department of Dermatology , University of Ulsan College of Medicine, Asan Medical Center , Seoul , Korea.
Do Young
do Y
Rhee
a Department of Dermatology , University of Ulsan College of Medicine, Asan Medical Center , Seoul , Korea.
Kwang Hee
KH
Won
a Department of Dermatology , University of Ulsan College of Medicine, Asan Medical Center , Seoul , Korea.
Ye Jin
YJ
Lee
a Department of Dermatology , University of Ulsan College of Medicine, Asan Medical Center , Seoul , Korea.
Chong Hyun
CH
Won
a Department of Dermatology , University of Ulsan College of Medicine, Asan Medical Center , Seoul , Korea.
Sung Eun
SE
Chang
a Department of Dermatology , University of Ulsan College of Medicine, Asan Medical Center , Seoul , Korea.
Mi Woo
MW
Lee
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000279:Administration, Cutaneous; D000369:Aged, 80 and over; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D000077271:Imiquimod; D007211:Indoles / Q000009:adverse effects*; D007636:Keratoacanthoma / Q000139:chemically induced*; D008545:Melanoma / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013449:Sulfonamides / Q000009:adverse effects*; D016896:Treatment Outcome; D000077484:Vemurafenib
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D000077271:Imiquimod
Vemurafenib; imiquimod cream; keratoacanthomas